港交所連升三日後股價回吐 兩手準備港交牛證51303、港交熊證52879
港股周三開市後,受到醫藥股所拖累,恆指走勢反覆向下,尾市時跌幅擴大至超過500點,全日下跌551點,收報210085點,險守21000點。
港交所(0388)近日股價走強屢有突破,惟周三午後港交所略有回吐,最新下跌1.2%,收報359.8港元。根據瑞銀周三資金流,大部分投資者將其持有的好倉沽出獲利離場,部分投資者或認為港交所升勢未能持續而反手部署港交所的相關淡倉。如投資者看好港交所,可留意港交牛證51303,收回價332港元,行使價330港元,23年2月到期,有效槓桿約11倍。如投資者看淡港交所,可留意港交熊證52879,收回價388港元,行使價390港元,23年2月到期,有效槓桿約11倍。
另外,最新有指內地不允許第三方平台直接進行藥品的網上銷售活動,醫藥股阿里健康(0241)、東京健康(6618)等股價暴跌13.9%及14.8%,同為醫藥股的藥明(2269)雖然主打並非互聯網醫療,但周三股價亦跟隨醫藥板塊下跌2.8%,收報69.1港元。如投資者希望部署博醫藥板塊股價反彈,看好可留意藥明牛證51339,收回價59港元,行使價57.5港元,23年3月到期,有效槓桿約5.6倍。如投資者看淡醫藥板塊會進一步受利淡因素所影響,看淡藥明可留意藥明熊證53112,收回價75港元,行使價76.5港元,22年12月到期,有效槓桿約8.9倍。
更多窩輪牛熊資訊:瑞銀認股證牛熊證網站: http://www.ubs.com/hkwarrants
輪證教學及巿況焦點短片:
https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber
謝宛彤
副董事
瑞銀亞洲股票衍生產品銷售部
本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人),並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發,其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌,投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止,屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險,並諮詢專業顧問及查閱有關上市檔。UBS Securities Hong Kong Limited為結構性產品之流通量提供者,亦可能是唯一報價者或巿場參與者。(C) UBS 2022。版權所有。~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.